Four States Pass Laws Allowing OTC Ivermectin, More States Pending Legislation - Pharmacy Times
Four states have passed laws allowing over-the-counter (OTC) sale of ivermectin, with more states considering similar legislation. This shifts ivermectin from prescription-only to OTC status in those states, impacting manufacturers, distributors, and pharmacies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that produce or distribute ivermectin products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately, as laws are effective upon passage; pending legislation may require proactive monitoring.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Ivermectin is now available OTC in four states, bypassing prescription requirements. This may affect labeling, distribution channels, and compliance with state vs. federal regulations.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that produce or distribute ivermectin products.
What you must do
Review state-specific OTC regulations for ivermectin; ensure product labeling and marketing comply with both FDA and new state OTC requirements; update distribution agreements and pharmacy contracts.
Deadline
Immediately, as laws are effective upon passage; pending legislation may require proactive monitoring.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)